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). It occurs in 5.3% of BD patients and may cause devastating complications. The etiology of BD is still unknown. An association between BD and HLA-B51 has been found in patients of many ethnic groups, but not in Western patients. 2 There is no curative treatment for BD, but the autoaggressive involvement of the immune system has suggested therapy with immunoablative intent for very severe, refractory patients.
Four patients (two male patients and two female patients) with intractable BD have been treated with autologous PBSCT. [3] [4] [5] Two were conditioned with Melphalan 200 mg/kg, 5 one with fludarabine, CY and ATG, 4 and one with the BEAM protocol following two mobilizations with CY 4 g/kg and G-CSF. 3 Two of these cases had remissions over 5 years, 5 but one relapsed after 90 days. 1 In a 10-year-old girl with intestinal BD having also developed a myelodysplastic syndrome (MDS) a cord blood SCT was followed by remission of both diseases. 6 We report here the first case of the literature, to our knowledge, in which an allogeneic BMT reversed a relapse of BD and was followed by a 2-year remission, after which there still was a relapse. In addition, a grade IV gastrointestinal/hepatic graft-versus-host disease (GVHD) was successfully controlled by a combination of cyclophosphamide (CY), photoimmune therapy and donor mesenchymal stem cells (MSC).
A 34-year-old (in 2006) lady started suffering with severe headaches and vertigo in 1992. She then presented aphthous oral, vaginal and intestinal bleeding ulcers in the following years. She was HLA-B51 negative, but a diagnosis of BD could be established according to the International Study Group for Behc¸et's Disease 1990 criteria. 7 In 2001, the headaches worsened, and the patient went into grade I coma. Computed tomography and multiple resonance imaging were negative, but SPECT studies showed multiple hypoperfusion areas. CSF examination showed 157 lymphocytes/ml. She responded very partially to corticosteroids, oral cyclophosphamide (CY) and mycophenolate mofetil (MMF). On August 28, 2002 CD34 þ cells were mobilized with 4 g CY. Distinct amelioration followed this procedure. In October 2002, she was conditioned according to the BEAM protocol and received her own CD34 þ cells (3.2 Â 10 6 /kg). She also received ATG 2.5 mg/kg on days þ 1 and þ 2. Hematologic recovery was within normality, and all symptoms receded. However, o3 months later, she had a severe relapse. She did not respond to IFN-a and to 3 g CY. She was given Infliximab, first 3 and then 5 mg/kg, remitted and relapsed after each administration. On 22 May 2003, she underwent BMT from her HLA-identical brother after conditioning with Thio-Tepa 10 mg/kg and CY 100 mg/kg. Cyclosporine and MTX were given for GVHD prophylaxis. Hematologic reconstitution was normal. Bone marrow cytogenetics were 100% 46,XY on day þ 75, and STR amplified loci analysis showed full chimerism on day þ 120. Starting from day þ 30 acute gastrointestinal and liver grade IV GVHD developed, with unfractionated bilirubin peaking at 564.3 mmol/l at day þ 120, alkaline phosphatase (ALP) 2475 UI/l and gamma-glutamil transpeptidase (GGT) 2940 UI/l. At that time aspartate transaminase (AST) was 379 UI/l, and alanine aminotransferase (ALT) 469 UI/l Liver biopsy was consistent with GVHD. Treatment consisted of corticosteroids, extracorporeal PUVA twice a week for 6 weeks, and two other interventions. CY 3 g was administered on day þ 100 and 50 Â 10 7 mesenchymal cells (MSC) from the same donor were given intravenously on day þ 140. Mesenchymal cells were isolated by seeding the donor's marrow-derived mononuclear cells at a density of 10 6 /ml in a 75 cut flask in Mesencult Medium (Stem Cell Techn., Vancouver, Canada). The following steps were performed according to a widely utilized procedure, 8 which is adhered to in our laboratory. Graft-versus-host disease resolved following these interventions, and all values were within normality by day þ 360 (Figure 1) . The patient had a complete remission of her original disease, which lasted approximately little o2 years, after which there was a reappearance of severe headache, sparse mucosal ulcers and rectal blood loss in two occasions. Treatment included four administrations of Rituximab according to the conventional protocol, plus photoapheresis CY 1 g and, on 19 December 2005, a second infusion of 65 Â 10 6 donor MSC because of the reappearance of GVHD. Brain SPECT examinations were performed by a twohead camera equipped by low-energy, high-resolution collimators, 60 min after intravenous injection of about 900 MBq of 99 m Tc-hexamethylpropilene amine oxime according to the current European guidelines. Seven SPECT examinations were performed along a 25-monthperiod. The several areas of asymmetry, consistent with the neuro-Behc¸et syndrome (CNS-NBs), have ameliorated significantly, but there appears to be a tendency for reappearance ( Figure 2 ). This is the first patient, to our knowledge, that underwent first an autologous and then an allogeneic SCT for severe, refractory CNS-NBs. There was a remission of 90 days following ASCT and of about 2 years following allo-BMT. In order to understand these relapses, especially after allo-BMT, it is of interest to consider that a study of cytokines in the CSF comparing CNS-NBs with multiple sclerosis (MS) has shown a mediator pattern resembling non-specific inflammation in CNS-NBs rather than bona fide autoimmunity, such as in MS. 9 Nevertheless powerful immunosuppression, as in ASCT, has been followed by remissions. 4, 5 That such remissions may be equivalent to cures seems improbable. Even in MS, a disease in which ASCT causes perhaps the most beneficial results, reappearance of autoreactive T cells to myelin basic protein after ASCT 10 demonstrates that the procedure, in spite of its clinical usefulness, is uncapable of eradicating minimal residual autoimmune disease, even if a new and diverse TCR repertoire has been shown to be generated by thymic output. 11 In addition, the persistence of the unknown, probably infectious, causative agent could perhaps also trigger the transplanted immune system to recognize the autoantigenic challenge, possibly via a cross-reactive mechanism.
A grade IV liver GVHD resolved following the combined effects of CY (3 g), photophoresis and administration of donor MSC. These last have been effective in grade IV liver GVHD by themselves alone 12 and have been shown to significally suppress T-cell activation. 13 In this patient, amelioration of GVHD had already started following CY, so that no specific evaluation is possible.
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